Rituximab Infusion Management

Introduction to Rituximab Administration

The American College of Oncology recommends that rituximab infusion does not routinely require overnight hospital admission, as most infusion-related reactions occur during or within the first 1-2 hours after infusion and can be safely managed in an outpatient setting with appropriate monitoring 1, 2

Infusion-related reactions occur in up to 77% of patients during their first infusion, with severe reactions (grade 3-4) occurring in approximately 10% of cases, according to the European Society for Medical Oncology 1, 2, 3
These reactions typically manifest during the infusion or within the first 1-2 hours after completion, not hours later, as stated by the American Society of Clinical Oncology 1, 3

The European Society for Medical Oncology recommends administering the first infusion at a slow initial rate with close monitoring of vital signs for at least 2 hours during infusion 1
The American College of Physicians recommends continuing monitoring for 1-2 hours after infusion completion, particularly for the first dose 3
All patients must receive antihistamine (e.g., diphenhydramine) and antipyretic (e.g., acetaminophen) 30 minutes before infusion, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2, 3

The American Society of Hematology recommends that high tumor burden patients, those with very high circulating lymphocyte counts (>25 × 10⁹/L), are at increased risk for severe cytokine release syndrome and may require split dosing over 2 days during the first cycle 1
The American Academy of Allergy, Asthma, and Immunology recommends that patients with prior grade 3-4 reactions who require desensitization protocols should be hospitalized 4
The National Kidney Foundation recommends that when rituximab is used with plasma exchange (e.g., in ANCA vasculitis), plasma exchange should be held for 48-72 hours after rituximab infusion, which may necessitate hospitalization depending on the clinical context 5

The American College of Physicians recommends screening patients by checking hepatitis B status, baseline immunoglobulins, and assessing tumor burden before rituximab infusion 6
The European Society for Medical Oncology recommends premedicating with antihistamine, antipyretic, and strongly considering corticosteroid (especially for first infusion) 1

The European Society for Medical Oncology recommends premedication with antihistamine (diphenhydramine 25-50 mg IV or PO) and antipyretic (acetaminophen 650-1000 mg PO) 30 minutes before infusion, as stated by the Annals of Oncology 7
Vital signs should be monitored regularly throughout the infusion, and any symptoms experienced by the patient must be taken seriously and vital signs evaluated immediately, as recommended by the Annals of Oncology 7
Medical staff should have emergency equipment readily available including epinephrine, oxygen, and IV fluids, as suggested by the Annals of Oncology 7

The American College of Physicians recommends screening for latent tuberculosis prior to administration of rituximab, as stated in the Mayo Clinic Proceedings 8